...
首页> 外文期刊>Neurotherapeutics >Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury
【24h】

Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury

机译:用于诊断,预后和治疗疗效的生物标志物对创伤性脑损伤的治疗疗效

获取原文
           

摘要

Traumatic brain injury (TBI) remains a serious health concern, and TBI is one of the leading causes of death and disability, especially among young adults. Although preventive education, increased usage of safety devices, and TBI management have dramatically increased the potential for surviving a brain injury, there is still a need to develop reliable methods to diagnose TBI, the secondary pathologies associated with TBI, and predicting the outcomes of TBI. Biomarkers (changes of amount or activity in a biomolecule that reflect injury or disease) have shown promise in the diagnosis of several conditions, including cancer, heart failure, infection, and genetic disorders. A variety of proteins, small molecules, and lipid products have been proposed as potential biomarkers of brain damage from TBI. Although some of these changes have been reported to correlate with mortality and outcome, further research is required to identify prognostic biomarkers. This need is punctuated in mild injuries that cannot be readily detected using current techniques, as well as in defining patient risk for developing TBI-associated secondary injuries.
机译:创伤性脑损伤(TBI)仍然是严重的健康问题,TBI是死亡和残疾的主要原因之一,特别是在年轻人中。虽然预防性教育,安全装置的使用量增加了,但TBI管理大大增加了患有脑损伤的可能性,但仍然需要开发可靠的方法来诊断TBI,与TBI相关的二次病理,并预测TBI的结果。生物标志物(反映伤害或疾病的生物分子中的量或活性的变化)在诊断若干条件下表现出承诺,包括癌症,心力衰竭,感染和遗传障碍。已经提出了各种蛋白质,小分子和脂质产品作为TBI脑损伤的潜在生物标志物。虽然据报道,一些这些变化与死亡率和结果相关,但需要进一步的研究来鉴定预后生物标志物。这种需求在轻度损伤中点击,使用当前技术不能容易地检测,以及定义患者风险以发展TBI相关的二次伤害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号